Seres Therapeutics

“We’ve got the right technology, the right team, the right science to change lives, and we're in the process of doing so.” Check out this recent #JPM2025 Flagship Pioneering CEO Chat with Eric Shaff as he explains how Seres is building on its experience developing VOWST, the first-ever FDA-approved oral life biotherapeutic, as it pioneers new therapies like SER-155 to address unmet need in in allo-HSCT. The full interview can be found here: https://lnkd.in/ej_xSteM

We’re excited to be back in San Francisco for #JPM2025! If you’re attending, don’t miss the chance to connect with the Seres Therapeutics leadership team: Eric Shaff, Marella Thorell, Terri Young, and Matthew Henn. Make sure to also mark your calendar for Thursday, January 16th, at 7:30 AM PST, when Eric will present a company overview. He’ll spotlight our plans to advance our innovative pipeline, including our lead program, SER-155. https://lnkd.in/eFRsd2_T

Today we're thrilled to announce that our lead live biotherapeutic, SER-155, has received Breakthrough Therapy Designation from the FDA for the reduction of blood stream infections in adults undergoing an allogeneic stem cell transplant. This designation ensures communication and guidance from FDA to expedite the development of medicines which are intended to treat serious or life-threatening diseases, and in which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint over available therapies. We look forward to working closely with the FDA in the new year to discuss the next SER-155 clinical study, which we believe could be a single registrational study for efficacy. Read more in our latest release: https://lnkd.in/ecZMqrVS

Our CEO Eric Shaff will be participating in a fireside chat at the upcoming Piper Sandler Annual Healthcare Conference on December 3rd. Can't make it to the event? We'll also be streamlining a live webcast through our website and will post the recording afterwards. Read the release: https://lnkd.in/gb7wJ_-q

Today we reported our Q3 financial results and provided business updates, including planned next steps for SER-155 following encouraging Phase 1b data in allo-HSCT patients. Read more in the full release: https://lnkd.in/eMfU2T7e

Today we’re pleased to share Cohort 2 data from our Phase 1b study evaluating SER-155 in patients undergoing allo-HSCT. Read the full release here: https://lnkd.in/ekKD-Tqf --- Summary of Cohort 2 Results (through day 100 post HSCT) - SER-155 was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia - SER-155 demonstrated a generally well tolerated safety profile and had confirmed drug bacteria strain engraftment; no treatment-related serious adverse events were observed - Seres will seek Breakthrough Therapy designation from the FDA and discuss plans to advance development of SER-155 in allo-HSCT.

Today we're excited to announce that we've signed the VOWST asset purchase agreement with Nestlé. The completion of the transaction, which is subject to Seres’ shareholder approval and other customary conditions, is expected to occur in the next 90 days.    Read the full release: https://lnkd.in/eZmJuF7y

Our team had a great time at Friday’s #BioBall event, sponsored by Special Olympics Massachusetts. Not only was it fun to get together for the afternoon, but we helped raise money to support our local #SpecialOlympics athletes! Check out the Special Olympics Massachusetts website to learn about the organization’s mission to support over 14,000 athletes with intellectual disabilities: https://lnkd.in/e48swYSF

Today we announced an exciting new chapter in our story as pioneers of microbiome therapeutics: an agreement with long-time partner Nestlé Health Science to acquire full rights to Vowst. This will allow us to focus on pursuing our mission of transforming the lives of patients by developing revolutionary medicines. https://lnkd.in/gGzxKtek

Seres is excited to present new preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at #ASCO24 in Chicago. Join us at the poster session on June 3rd at 9am CDT. Learn more: https://lnkd.in/e7wYXuWE